Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF)

The QualityStocks Daily Newsletter would like to spotlight Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF).

AI Transforms Mining: AI speeds up mineral discovery by analyzing large datasets, predicting drill targets, and improving operational efficiency.

A McKinsey report estimates that AI could unlock $290 billion to $390 billion in annual savings for producers of key resources by 2035.

Emperor Metals' Advantage: At Duquesne West, Emperor Metals used AI and DomainMCF to develop a 3D geological model, accelerating discovery and unlocking new high-priority exploration targets.

As the global mining industry faces mounting pressures to boost productivity, reduce costs and minimize its environmental impact, artificial intelligence ("AI") is emerging as a necessary evolution. A 2022 McKinsey report estimates that AI could unlock $290 billion to $390 billion in annual savings for producers of key resources by 2035.

At the forefront of AI-driven exploration is Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FSE: 9NH), a junior mining firm based in Quebec. The company has integrated AI into its flagship Duquesne West Gold Project in Quebec's Abitibi Greenstone Belt, a prolific Canadian gold mining distinct currently hosting 15 producing gold mines.

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF) is an advanced stage gold exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project located in the Tier 1 district of the Southern Abitibi Greenstone belt of Rouyn-Noranda, Quebec. The Project has a 2011 historical mineral resource estimate of 727,000 ounces of Au at 5.42 g/t and an average thickness of 5.71 m*.

In 2023, with the use of AI (Artificial Intelligence), Emperor Metals created the first ever 3D mineralized and geological model, which illuminated the potential to add significant ounces to this deposit. Using these models, Emperor’s had a very successful 2023 drilling campaign of 8,579 m. In addition to laterally extending high grade zones by intercepting grades of 15.8 g/t Au over 10.8 meters, Emperor encountered intercepts of lower grade bulk tonnage in the host rocks (1.69 g/t Au over 25 m). This led to envisioning a different strategy of exploration and the revelation that a conceptual open-pit potentially overlies this high-grade gold deposit. Historic core sampling began (2,500 m) for discovering overlooked lower grade gold in the host rock around the high-grade lenses. Lower grade bulk tonnage gold improves the open-pit economics by reducing stripping ratios and adding overlooked incremental ounces for open pit mining.

Emperor Metals is set to begin a fully funded Phase II 8,000 m drilling program in May 2024. The company also plans on assaying an additional 8,000 m of historic core within the open pit model. Emperor is working toward producing an updated NI 43-101 Mineral Resource Estimate by Q1 2025.

The company is led by a dynamic group of resource sector professionals who have a strong record of success in evaluating and advancing mining projects from exploration through to production, attracting capital and overcoming adversity to deliver exceptional shareholder value.

Project

Emperor Metals has an option to earn 100% ownership of the Duquesne West Gold Project, a mineral claim package comprising 38 claims covering approximately 1,389 ha (3,432 acres) in Quebec.

The Duquesne West Gold Property is located 32 kilometers northwest of the city of Rouyn-Noranda and 10 kilometers east of the town of Duparquet. The property lies within the historic Duparquet gold mining camp in the southern portion of the Abitibi Greenstone Belt in the Superior Province.

Emperor is targeting the potential multimillion-ounce resource in a combination of conceptual open pit and underground mining scenarios. A Phase I drill campaign and historical core sampling program was completed in 2023, which included resource confirmation and exploration drilling, focusing on delineating and growing the resource toward development.

The property hosts a historical inferred mineral resource estimate of 727,000 ounces of gold at a grade of 5.42 grams per ton (g/t) and average stope thickness of 5.71 m. The mineral resource estimate predates modern Canadian Institute of Mining guidelines, and a Qualified Person on behalf of Emperor Metals has not reviewed or verified the mineral resource estimate. Therefore, it is considered historical in nature and is reported solely to provide an indication of the magnitude of mineralization that could be present on the property. The gold system remains open for resource identification and expansion.

Reinterpretation of the existing geological model was created using artificial intelligence and machine learning. This AI model shows the opportunity for additional discovery of ounces by revealing gold trends unknown to previous workers and the potential to expand the resource along significant gold-endowed structural zones. Multiple scenarios exist to expand additional resources, which include:

• Underground High-Grade Gold
• Open Pit Bulk Tonnage Gold
• Underground Bulk Tonnage Gold

The Duquesne West-Ottoman property straddles the Porcupine-Destor gold localizing fault several kilometers east of the town of Duparquet. A number of previous drill campaigns have outlined an inferred resource of 4.17 million tons grading 5.42 g/t of gold (cut) or 6.36 g/t (uncut), as reported in the NI 43-101 report titled “Technical Report and Mineral Resource Estimate Update for the Duquesne-Ottoman Property, Quebec, Canada.”

Emperor Metals is funded for an 8,000-meter drilling program focusing primarily on adding ounces to the current resource within and lateral to the open pit model. An additional 8,000 m of historical core sampling and assaying is included in the budget to help build incremental ounces in the open-pit environment.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, to be worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

In May 2024, the market price of gold was approximately $2,340 per ounce.

Management Team

John Florek, P.Geol., is President, CEO and Director of Emperor Metals. He has more than 35 years of technical and senior management experience with major and junior mining companies, including roles as founder, vice president and director. He has helped identify and develop significant asset value for mines and exploration projects from grass roots through development. He has worked for several major mineral producers, including BHP, Placer Dome, Barrick, Teck and Detour Gold/Kirkland Lake Gold/Agnico Eagle.

Sean Mager is CFO and Director of Emperor Metals. He has worked more than 30 years in the mining sector, including extensive experience in corporate development, stakeholder relations, regulatory, financial and operations.

Alex Horsley is Head of Corporate Development and Director of Emperor Metals. He has more than 20 years of experience in the mining sector and capital markets with a focus on finance, marketing, management, corporate development and communications. He is founder and former CEO of Emperor Metals. He has assisted in raising more than C$40 million for exploration and development mining companies.

*Power-Fardy and Breede, 2011. The Mineral Resource Estimate (MRE) constructed in 2011 is considered historical in nature as it was constructed prior to the most recent Canadian Institute of Mining and Metallurgy (CIM) standards (2014) and guidelines (2019) for mineral resources. In addition, the economic factors used to demonstrate reasonable prospects of eventual economic extraction for the MRE have changed since 2011. A qualified person has not done sufficient work to consider the MRE as current. Emperor is not treating the historical MRE as current. The reader is cautioned not to treat it, or any part of it, as a current MRE.

Emperor Metals Inc. (OTCQB: EMAUF), closed Thursday's trading session at $0.0637, up 2.7419%, on 2,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.05715/$0.14505.

Recent News

• Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF) - How AI is Transforming Mineral Discovery and Driving Efficiency
• MiningNewsBreaks - Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH) Viewed as Substantial Opportunity in Promising Sector
• Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FSE: 9NH) Has More Going For It Than Unprecedented Gold Prices

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Following the enactment of emergency regulations to ban intoxicating hemp products in the state of California, players in the hemp industry filed a lawsuit against the state's Department of Public Health to overturn the rules. Now plaintiffs in the lawsuit are requesting a state judge to halt the enforcement of the regulations until a ruling is given by the courts on the matter. In their suit, the plaintiffs argue that the ban is unlawful and will cause irreversible damage to the nascent hemp industry. The new request argues that allowing the regulations to remain in effect would eliminate almost every ingestible hemp product currently being sold in the state, including the majority of nonintoxicating products. This means that many small businesses will have to halt their operations, which will result in losses worth millions of dollars. A hearing on the proposed temporary restraining order is set for later this week in Los Angeles. The plaintiffs include the U.S. Hemp Roundtable, Cheech and Chong's Global Holdings, Sunflora, Lucy to Be Beverage, Boldt Runners, Blaze Life and Juicetiva. This patchwork of regulations in different states gives businesses such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) more hurdles to navigate as they conduct their legal business activities. A suitable way out would be for the federal government to come up with comprehensive regulations for cannabinoids so that interested parties can have one law to refer to when conducting their operations.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Thursday's trading session at $0.026, up 8.3333%, on 47,332 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

• Software Effective Solutions Corp. (OTC: SFWJ) - California Hemp Industry Launches Legal Challenge to Newsom's THC Ban
• InvestorNewsBreaks - Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
• Georgia Hemp Industry Contends with New Regulations

SOBRsafe Inc. (NASDAQ: SOBR)

The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

Alcohol detection and monitoring devices have been in use for years, but the need for faster, discreet technology capable of delivering real-time results became more apparent in the mid-2010s

In 2015 and 2016, the NIAAA announced challenges seeking alcohol monitoring solutions that provide real-time results; the winning entries were wearable wristbands still at the prototype stage

Fast-forward to today, and SOBRsafe, a company providing next-generation alcohol detection technology, commercializes its market-validated SOBRcheck(TM) stationary alcohol screening device and the SOBRsure(TM) wearable wristband

SOBRsafe's devices feature highly precise sensors that are calibrated for early, low alcohol detection, beginning at about 20 minutes, compared to 45-60 minutes for the leading mandatory ankle monitor

The company believes its disruptive breakthrough technology could become the global standard for alcohol monitoring and detection, replacing legacy products and testing methods

In 2015 and 2016, the National Institute on Alcohol Abuse and Alcoholism ("NIAAA"), a part of the National Institutes of Health ("NIH"), challenged innovators and entrepreneurs to create a "wearable or otherwise discreet device capable of measuring blood alcohol level in real-time." The challenge aimed to help solve the disadvantages of the then-preferred technologies for alcohol monitoring. "Current technology for continuous alcohol monitoring takes a reading every 30 minutes. We are seeking a solution that improves on this interval and most closely approximates real-time monitoring and data collection," stated the circular from NIAAA explaining the rationale behind the 2015 challenge (https://ibn.fm/EhUO8). The winners designed wearable wrist monitors that measure transdermal alcohol concentrations ("TAC") (https://ibn.fm/fpXye). While these winning entries were prototypes, the competition perhaps inspired the modern alcohol detection and monitoring landscape. Today, there are validated, commercially available transdermal alcohol monitoring devices available on the market, some more capable than others. One company in particular, SOBRsafe (NASDAQ: SOBR), commercializes its SOBRcheck(TM) stationary screening and SOBRsure(TM) wearable monitoring solutions, which utilize a proprietary transdermal technology that simplifies the alcohol detection process. According to the company, the SOBRsafe transdermal detection technology pairs a NIAAA-awarded transdermal gas sensor with proprietary algorithms to capture alcohol vapor excreted through skin pores alongside other contents of sweat.

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.

Products

The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.

SOBRsafe™

With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.

SOBRcheck™

SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.

SOBRsure™

SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.

 

Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Thursday's trading session at $6.89, off by 4.4383%, on 114,301 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.70/$110.00.

Recent News

• SOBRsafe Inc. (NASDAQ: SOBR) - SOBRsafe Inc.'s (NASDAQ: SOBR) Disruptive Technology Poised to Become the Global Standard for Alcohol Monitoring and Detection
• InvestorNewsBreaks - SOBR Safe Inc. (NASDAQ: SOBR) Closes on $8.2M Private Placement
• InvestorNewsBreaks - SOBR Safe Inc. (NASDAQ: SOBR) Reports on Private Placement Valued at Estimated $8.2M

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Proceeds from the offerings will support the company's operations into the first quarter of 2025.

Clene also amended its existing debt facility with Avenue Venture Opportunities Fund, L.P. to reduce or defer future monthly principal payments and to extend principal amortization period and the final maturity date into the first half of 2025.

The company's lead drug candidate, CNM-Au8® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions.

Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS, with a meeting scheduled with the FDA before the end of November.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") multiple sclerosis ("MS") and Parkinson's Disease ("PD"), announced the successful closing of a $7.3 million registered direct offering and concurrent private placements, designed to boost its capital position during a crucial phase in its on-going operations.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $5.51, off by 5.812%, on 66,155 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.8181/$12.00.

Recent News

• Clene Inc. (NASDAQ: CLNN) - Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements
• InvestorNewsBreaks - Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
• InvestorNewsBreaks - Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company announced Thursday morning that it participated in a Virtual Investor KOL Connect segment. Members of the company's management team and Dr. Samuel Goldlust, who previously served as an investigator in the company's global potentially pivotal study of Berubicin, joined the segment to provide a corporate update, discuss the unmet need in glioblastoma multiforme ("GBM"), and highlight the opportunity for the company.

To access the segment, visit https://ibn.fm/V1eC1

To view the full press release, visit https://ibn.fm/rAdeF

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $0.1174, off by 4.1633%, on 1,182,663 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0955/$6875.00.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment
• InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit
• Jimmy Carter Survival Thanks to Novel Cancer Immunotherapy Treatment

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

Fathom Nickel (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF), an exploration company targeting magmatic nickel sulphide discoveries to support the rapidly growing global electric vehicle market, will be participating at the upcoming Red Cloud Fall Mining Showcase. The in-person event is scheduled for Oct. 16–17, 2024, in Toronto. According to the company, Fathom Nickel's CEO and VP of exploration Ian Fraser will be presenting during the annual conference; Fraser's presentation is scheduled to begin at 10 a.m. EST on Oct. 17.

To register or learn more about the event, visit https://ibn.fm/SPKEZ

To view the full press release, visit https://ibn.fm/Yo1yM

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.

Projects

The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Thursday's trading session at $0.026405, off by 2.2037%, on 10,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.013465/$0.17.

Recent News

• Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) - InvestorNewsBreaks - Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Executive to Participate at Red Cloud's 2024 Fall Mining Event
• MiningNewsBreaks - Fathom Nickel Inc.'s (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Geochemistry Program Reveals Remarkable 25-Fold Increase in Geochemical Footprint
• US Nickel Mine Strives to Be Trailblazer in Greening Mining Operations

Dynasty Gold Corp. (TSX.V: DYG) (OTC: DGDCF)

The QualityStocks Daily Newsletter would like to spotlight Dynasty Gold Corp. (TSX.V: DYG) (OTC: DGDCF).

Dynasty Gold (TSX.V: DYG) (FSE: D5G1) (OTC: DGDCF), a Canadian mineral exploration company, today announced results from its 2024 annual general meeting held on October 4, 2024. The company reported that all resolutions were approved and that Ivy Chong, Roman Shklanka, Larry Kornze, and Richard Redfern were elected directors until the next annual general meeting. The company also provided an update on the drilling progress at its Thundercloud Project, capturing the results from the three drilling campaigns conducted between 2022 and 2024. "This project looks very promising of becoming a mine, given these grades and shallow intercepts," said Roman Shklanka, Ph.D. (Geology), Director.

The company expects to soon receive more results from the recently completed drill program. Dynasty also reported that an exploratory drill program in the West Contact zone, which aims to further test the currently obtained trench assay of 8.04 g/t over 39 meters, was underway. According to the announcement, Dynasty maintains a solid financial position with no debt and about 61 million shares issued and outstanding.

To view the full press release, visit https://ibn.fm/3UEfc

About Dynasty Gold Corp.

Dynasty Gold Corp. (TSX.V: DYG) (OTC: DGDCF) is rapidly emerging as a notable player in the gold sector. With its impressive portfolio of high-potential projects and recent drilling results, Dynasty Gold is capturing the attention of investors and industry analysts alike. As the company continues to advance its exploration efforts, the potential for substantial gains becomes increasingly evident.

Many respected analysts agree that gold is in the early stages of a new commodities supercycle, where multiple forces like inflation, infrastructure spending, and global demand are driving the price surge. The question is, ‘how to profit from it’.

Dynasty Gold’s recent drilling campaign at its flagship Thundercloud project in Ontario, Canada, has delivered results that are likely to reshape expectations and could significantly impact the company’s fortunes. The latest drilling assays from the project reveal high-grade gold mineralization, confirming the project’s potential for substantial resource development.

With high-quality North American assets, renowned leadership and a miniscule market cap, Dynasty Gold looks perfectly positioned to capitalize on any potential updraft in prices and potentially deliver outsized returns. In fact, if the next batch of drill holes (expected within weeks) is successful in expanding the economics of the resource, DYG could easily outperform the market and lead the pack to the upside.

There are only about 61 million Dynasty shares issued and outstanding, with roughly 40% owned by insiders and long-term shareholders. It’s important to note that Rob McEwen owns 9.7%. A mining legend, McEwen founded Goldcorp and increased the company’s market cap 160X – from $50M to over $8B. He must see value in Dynasty Gold, too. Around 50% of outstanding shares are held by retail investors, and any positive news on top of surging global demand could catapult the stock.

High-Grade Deposits, 100% Owned

The Thundercloud Property

The Thundercloud property is situated in the prolific Archean Manitou-Stormy Lakes greenstone belt in Western Ontario, which has a geological setting similar to the Abitibi belt but is much less thoroughly explored. The region contains numerous gold showings, along with several deposits and historic producers. Initial results suggest excellent potential for bulk-tonnage orogenic gold mineralization, with the possibility of high-grade mineralization. In recent years, nearly 30 million ounces of gold have been discovered in the area.

Dynasty Gold’s Thundercloud project is strategically located within one of Canada’s most prodigious gold-producing regions. Ontario is renowned for its rich mineral deposits and supportive mining infrastructure, providing a favorable environment for exploration and development. The Thundercloud property covers approximately 5,560 acres and is located 47 kilometers southeast of Dryden, Ontario. It is accessible via the Trans-Canada Highway (Hwy 17). Dryden, a resource-based town, offers essential infrastructure for mining operations.

Dynasty recently completed Phase 1 of its 2024 Drill Program at its Thundercloud property, announcing results in an August press release.

Ivy Chong, President and CEO, commented, “Dynasty completed Phase 1 of the 4,000 meters planned drilling, consisting of 11 holes for a total of 2,198 meters. The eight holes within the Pelham Zone all intersected intervals from 10+ to 70 meters of strong pyrite veinlets and disseminations similar to that associated with high-grade mineralization in the previous two years of grades up to 8.4 g/t gold over 73.5m including 151.7 g/t gold over 3.0m. We look forward to receiving the assay results from Phase 1 drilling within the next several weeks and will re-commence drilling in early September, once these results have been analyzed and an additional 10 or more drill holes sited.”

The recent drilling results at Thundercloud have substantial implications for the project’s future. High-grade gold intercepts are indicative of a robust mineralized system, which could lead to a significant increase in the project’s resource estimate. Despite this high-grade, the company’s drill holes are comparatively shallow (less than 250 meters in length). Many similar projects are required to drill as deep as 700+ meters to obtain grades similar to Dynasty’s recent results. This, in turn, enhances the project’s attractiveness to major mining companies and institutional investors.

The impressive drilling results from Dynasty’s Canadian project will be followed by more drilling with more news expected in the next few weeks. Roughly 90% of the project has thus far seen limited drilling and therefore represents untested potential. Positive assay results often generate increased interest and confidence as the market reacts to the potential for significant resource discoveries.

The Golden Repeat Property

Located on the north slope of the Midas Trough, along the Carlin Trend within the Northern Nevada Rift, the Golden Repeat gold property comprises 49 contiguous mining claims totaling approximately 968 acres. These claims share geological similarities with gold properties in the well-known Midas Gold Camp.

Hecla Mining Company’s Midas Mine is located 18 kilometers east of the property, with other major Carlin-style gold mines, including Nevada Gold Ventures LLC’s Getchell-Twin Creeks-Turquoise Ridge mines (15 kilometers southwest) and its Goldstrike Mine complex (50 kilometers southeast) nearby.

The property is easily accessible from Interstate 80, with excellent local mining infrastructure. Gold Fields and Romarco Minerals briefly drilled the property in the 1990s, but a large portion remains unexplored.

Market Opportunity

In 2023, the World Gold Council estimated the physical financial gold market – comprising bars, coins, gold ETFs, and central bank reserves – was valued at nearly $5 trillion.

This historical scarcity and relatively slow rate of new production, compared to other commodities, are key reasons gold has retained its value for millennia. In September 2024, the spot price of gold was quoted at just over $2,497 per ounce.

Dynasty Gold’s strategic focus on expanding its resource base and advancing its exploration efforts positions it well for future success. The company’s ongoing drilling programs are designed to further delineate and expand the high-grade zones identified, which could lead to a substantial resource upgrade and increased project valuation.

Additionally, the potential for resource expansion and the attractiveness of Dynasty Gold’s project in a top-tier mining jurisdiction such as Ontario could attract interest from strategic partners or acquisition targets. Options include both smaller scale high-grade production in the near term or bulk tonnage production in the years ahead. Such developments would provide additional opportunities for capital infusion and project acceleration, further supporting a positive trajectory for the stock price.

Management Team

Ivy Chong has served as CEO of Dynasty Gold since 2008. With over two decades of experience in the mining and oil & gas industries, she has negotiated several option and joint venture agreements with major companies such as Teck, AngloGold Ashanti, Azimut, and Avocet Mining. She has assisted numerous companies with IPOs and raised capital for resource firms across Asia, Europe, and North America. Before entering the resource industry, she worked at the Hong Kong Stock Exchange and Deloitte and Touche LLP.

Larry Kornze, VP of Exploration and Director at Dynasty Gold, brings over 30 years of international gold exploration experience to the company. He is credited with discovering Barrick’s 40-million-ounce gold deposit at the Betze Mine on the Carlin Trend in Nevada during the late 1980s. Kornze was also involved in the discovery of other significant deposits in Nevada, including Miekle, Deepstar, Screamer, and Rodeo. He has held positions with Newmont and Getty Mining in North America and serves on the boards of several public gold exploration companies.

Dynasty Gold Corp. (OTC: DGDCF), closed Thursday's trading session at $0.089, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.077/$0.1893.

Recent News

• Dynasty Gold Corp. (TSX.V: DYG) (OTC: DGDCF) - Dynasty Gold Corp. (TSX.V: DYG) (OTC: DGDCF) Launches Second Phase of 2024 Drill Campaign at Flagship Thundercloud Property
• InvestorNewsBreaks - Dynasty Gold Corp. (TSX.V: DYG) (FSE: D5G1) (OTC: DGDCF) Commences Phase Two of 2024 Exploration Program at Thundercloud Property
• Dynasty Gold Corp. (TSX.V: DYG) (OTC: DGDCF) Thundercloud Drilling Reveals Up to 24.53 g/t High-Grade Gold Intercepts

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

• Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
• Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
• Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
• Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
• Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
• Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Thursday's trading session at $1.97, up 14.5349%, on 269,767 volume. The average volume for the last 3 months is 491,273 and the stock's 52-week low/high is $1.45/$350.00.

Recent News

• Freight Technologies Inc. (NASDAQ: FRGT) - InvestorNewsBreaks - Freight Technologies Inc. (NASDAQ: FRGT) Selected by Bayer as 'Key Logistics Provider'
• InvestorNewsBreaks - Freight Technologies Inc. (NASDAQ: FRGT) Releases Mid-Year 2024 Financial Results
• InvestorNewsBreaks - Freight Technologies Inc. (NASDAQ: FRGT) Reaches Agreement to Extinguish $1.1M of Outstanding Debt, Convertible Notes

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

• PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
• PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
• PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
• Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Thursday's trading session at $0.1299, up 12.9565%, on 43,203 volume. The average volume for the last 3 months is 74,462 and the stock's 52-week low/high is $0.061/$10.26.

Recent News

• PaxMedica Inc. (NASDAQ: PXMD) - Study Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD Patients
• InvestorNewsBreaks - PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K
• Yale Study Unravels Autism, Brain Growth Patterns

Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF)

The QualityStocks Daily Newsletter would like to spotlight Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF).

Annovis Bio Inc. Overview

Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) is an active mineral exploration company engaged in the exploration and development of the company’s wholly owned multi-commodity mineral properties in Canada. The company owns the Parbec gold deposit on the Cadillac Break in Quebec and is currently exploring the Parbec property to increase the gold resource and identify a location to strip and bulk sample from surface.

In addition, the company holds the Nixon Bartleman gold property in Ontario and is also engaged in developing its wholly owned Malartic Metals Package, Quebec’s newest polymetallic battery minerals district with several areas of mineralization, one of which is the nickel, cobalt, copper and zinc mineralized Victoria structure boasting approximately 20 kilometers of strike with surface mineralization, limited drilling, road access and hydroelectric power.

Renforth is well positioned in the heart of the Abitibi Greenstone belt, which straddles the Canadian Provinces of Ontario and Quebec, on both of the Cadillac-Larder Lake and Destor-Porcupine faults – the two main structures responsible for a belt endowed with more than 300 million ounces of gold (including production, M&I reserves and resources to date), making it one of the world’s most prospective gold regions.

The Canadian Malartic Mine, one of Canada’s largest gold mines, is adjacent to each of Renforth’s brownfield Malartic area properties, the Parbec open pit gold resource and the Malartic Metals Package, which, in addition to several known battery metals mineralized structures, also hosts gold within the Pontiac sediments, a very under-explored geological setting.

The company is headquartered in Pickering, Ontario.

Projects

Parbec Gold Deposit

Renforth’s 100% owned Parbec Gold Deposit contains a gold resource designed with an open pit to capitalize on Parbec’s surface mineralization. An MRE on the project, effective December 2019 and now considered by Renforth to be obsolete, is based upon approximately 28,000 meters of drilling which occurred between 2007 and 2019.

Renforth drilled 15,000 meters of new holes in 2020 and 2021 which were not included in the MRE, but which did extend the mineralization deeper within the MRE. The 2020-21 drilling is considered to have validated an additional 13,000 meters of historic drilling from 1986-93.

The validation occurs as 10% of the historic holes were redrilled, with results comparable to the historic results in terms of geology and gold values. Any future MRE calculated at Parbec will benefit from the inclusion of the new and historic drilling.

In addition to this, Renforth’s current structural interpretation on the location of, and controls on, the gold mineralization at Parbec is materially different than the geological model for the outdated MRE. For the first time, Renforth has mapped the Pontiac contact and interpreted a hinge fold interacting with the Cadillac Break and allowing the movement of gold enriched fluids, with mineralization plunging to the south, into the Pontiac.

It is worth noting that a structural control on the adjacent, and much larger, Canadian Malartic Mine is the Sladen Fault transiting into the Pontiac. Currently, Renforth is testing this interpretation with a soil survey designed to outline an area for stripping and bulk sampling within the Pontiac south of the Cadillac Break.

Malartic Metals Package

Renforth’s wholly owned approximately 300-square-kilometer Malartic Metals Package in Quebec’s mining heartland includes surface mineralization of battery metals nickel, cobalt, copper, zinc and silver in separate structures, as well as a copper/silver discovery and gold mineralization. Lithium is also present in anomalous amounts in the sediments, though the source has not yet been located.

The property was assembled commencing in 2020 by adding claims to Renforth’s existing Malartic West property by map staking. The goal was to acquire historic gold and base metal showings, as well as pronounced magnetic anomalies, joining several of the areas of discrete historic exploration into a district scale property with several areas of interest for battery metals and a greenfield copper/silver discovery. The property benefits from its location in an established mining community, roads on the property, rail just off the property and hydroelectric power lines crossing the property, making logistics simple and the cost to operate quite low.

This is the first time this property has been assembled as it is today and actively explored. A significant portion of the property has never been explored.

Market Overview

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council. In August 2024, the market price of gold was approximately $2,435 per ounce.

Management Team

Nicole Brewster is President and CEO of Renforth Resources. During her tenure she has reconstituted the company, developed a maiden mineral resource and sold a gold deposit. She is a native of the Toronto area and has been around the mining business nearly all her life, having been raised by a successful mineral exploration geologist who worked (and is still working) around the world as an entrepreneur and geoscientist.

Ms. Brewster worked summer jobs in various segments of the mining business, which led to her employment as a contractor working in the early days of the digitization of exploration data, 3D modeling and data visualization. After working in the capital markets for a time, she returned to the mineral exploration business as a partner in a successful private firm with several employees.

Renforth Resources Inc. (OTCQB: RFHRF), closed Thursday's trading session at $0.0138, even for the day. The average volume for the last 3 months is 19,485 and the stock's 52-week low/high is $0.0068/$0.0242.

Recent News

• Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) - Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) Positioned to Become Dynamic Player in Renowned Malartic Mining Region
• InvestorNewsBreaks - Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) (FSE: 9RR) Featured in Latest Episode of The MiningNewsWire Podcast
• MiningNewsBreaks - Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) (FSE: 9RR) 'Delivering on Multiple Fronts' with Completed and Ongoing Exploration Efforts